Automating the Determination of Drug-to-Antibody Ratio of Antibody Drug Conjugates.
Learn about Waters' end-to-end and automatable workflow using our integrated UPLC/QTof-MS analytical technologies. We demonstrate that, by using our efficient method deployment approach, this workflow can help you maintain high productivity in ADC characterization.
Antibody drug conjugates represent a rapidly growing class of biotherapeutic drugs for the treatment of cancer.
ADCs offer the selectivity of an antibody with the potency of a cytotoxic agent such as a synthetic drug.
ADC design, in part, relies on predictable conjugation chemistry that preserves antibody binding activity while facilitating reproducible characteristics that can be used as metrics for assessing critical quality attributes (CQAs) to ensure a safe and effective ADC product.
Download the application note pdf file HERE